HIGHLIGHTS
- who: . and collaborators from the Institute of Hematology and Transfusiology (IHT), Poland Nanchang University, China have published the paper: ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK, in the Journal: (JOURNAL)
- how: Frontiers in Pharmacology frontiersin.org 10.3389/fphar.2022.1071114 ASK120067 blocked BTK/ITK activation in malignant cell lines Next the authors conducted molecular modeling to simulate the binding between ASK120067 and BTK or ITK to illustrate the underlying structure-activity relationship (SAR). The results showed that ASK120067 dose-dependently suppressed anti . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.